Patent application number | Description | Published |
20080233591 | METHOD AND TEST KIT FOR QUANTITATIVE DETERMINATION OF POLYNUCLEOTIDES IN A MIXTURE - The invention relates to a method and test kit for quantitative determination of the amounts or relative proportions of polynucleotides in a mixture. The invention enables assessment of dynamic variations in a mixed population of organisms using affinity aided solution hybridization. The test kit comprises organized pools of polynucleotide probes having approximately the same number of nucleotides, which are distinguishable using resolution enabling tags providing the probes with different sizes. The resolution enabling tags may simultaneously act as tracer, affinity or primer tags. The probes are allowed to hybridize with affinity tagged analyte polynucleotides. The result is hybrids, recoverable on separation aiding tools provided with counterparts of the affinity tag. After the quantitative release of the probes, the individual probes can be amplified and recorded. The method and test kit are useful for determining hygienic and epidemiologic situations and evaluating the effect of antibiotic treatment and sanitary measures. | 09-25-2008 |
20100086552 | ALLERGEN-BINDING IGE MONOCLONAL ANTIBODIES AND METHOD FOR PREPARING HYPOALLERGENS - The present invention relates to human IgE antibodies and derivatives thereof, which bind non-continuous planar allergenic epitope, such as in β-lactoglobulin, with high affinity and specificity. The present invention also relates to processes for making and engineering such allergen binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics and immunotherapy. | 04-08-2010 |
20100292095 | HUMAN MONOCLONAL ANTIBODIES DIRECTED TO SIALYL LEWIS C, SIALYL TN AND N GLYCOLYLNEURAMINIC ACID EPITOPES AND A METHOD OF ANALYSIS OF STEM CELLS COMPRISING SAID EPITOPES - This invention relates to antibody engineering technology. More particularly, the present invention relates to human IgM antibodies and derivatives thereof, which have novel binding specificity with regard to several oligosaccharide sequences and/or xenoantigenic sialic acid residue. The present invention also relates to processes for making and engineering such novel saccharide and/or NeuGc-binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics, enabling qualitative and quantitative determination of xenoantigenic NeuGc in biological and raw material samples, as well as in immunotherapy, enabling blocking of xenoantigenic NeuGc in patients. | 11-18-2010 |
20110086364 | DETECTION OF CANNABIS USE - A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of | 04-14-2011 |
20110104190 | MODIFIED BETA-LACTOGLOBULINS FOR IMMUNOTHERAPY OF MILK ALLERGY - The present invention is related to field of allergic (hypersensitivity) diseases and provides a method for producing modified allergenic polypeptides for use in immunotherapies. In the method of the invention, said allergenic polypeptides are modified so that they are not capable to form transient dimers. The invention also provides modified β-lactoglobulins for use in immunotherapy of milk allergy. | 05-05-2011 |
20140037663 | HYPOALLERGEN - The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant Bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies. Furthermore, the invention provides vaccine formulations comprising such polypeptides; the use of such formulations; and to methods of vaccination against birch pollen allergy. | 02-06-2014 |
20140044744 | NOVEL HYPOALLERGENS - The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant Bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies. Furthermore, the invention provides vaccine formulations comprising such polypeptides; the use of such formulations; and to methods of vaccination against birch pollen allergy. | 02-13-2014 |